Chemotherapy: Open Access
Open Access

Recent Strategies of Pancreatic Carcinoma

Georg Weber^{* *}Correspondence: Georg Weber, Department of General and Visceral Surgery, Friedrich Alexander University, Erlangen, Germany, Email:

Author info »

Description

Pancreatic cancer is one of the greatest lethal malignancies and is associated with a poor prognosis. Surgery is considered the only potential curative treatment for pancreatic cancer, shadowed by adjuvant chemotherapy, but surgery is earmarked for the minority of patients with non-metastatic resectable tumors. In the future, neoadjuvant treatment strategies grounded on molecular testing of tumor biopsies may increase the amount of patients flattering eligible for surgery. In the context of nonmetastatic disease, patients with resectable or borderline resectable pancreatic carcinoma might advantage from neoadjuvant chemo- or chemoradiotherapy shadowed by surgery. Patients with locally progressive or metastatic tumors presenting significant retort to chemotherapy should undergo surgery if R0 resection appears to be achievable. New immunotherapeutic strategies to persuade potent immune response to the tumors and examination in molecular mechanisms heavy tumorigenesis of pancreatic cancer may deliver novel therapeutic chances in patients with pancreatic carcinoma and help patient assortment for optimal treatment.

Pancreatic cancer is one of the most lethal malignancies, accounting for the 7th leading cause of cancer-related humanity worldwide. Though progress has been made in multimodality treatment with surgery and adjuvant therapy, the humanity rate of pancreatic cancer is still cumulative through the years. The unsatisfactory prognosis of this disease is mainly attributable to its late diagnosis, as most patients with pancreatic cancer continue asymptomatic until the disease grows to an advanced stage. Also, tumor biology of pancreatic cancer may donate to its initial metastasis. A preclinical study using a mouse model of pancreatic cancer designates that early metastasis might perhaps be noticed even when there is no primary tumor originate in the pancreas and is related with epithelial-to-mesenchymal transition and focal inflammation. Consequently, like many other types of cancers, pancreatic cancer is optional to be a systematic disease, and multidisciplinary management of this disease is of great standing. Treatment of pancreatic cancers chemotherapy includes surgery, radiation therapy, and palliative care, which are selected on the basis of disease stage.

In patients with borderline resectable disease, biopsy confirmation of adenocarcinoma with endoscopic ultrasoundguided fine needle aspiration (EUS-FNA), CT-guided biopsy, or staging laparoscopy is obligatory. After ruling out metastatic disease, neoadjuvant chemotherapy or chemoradiotherapy is practical, preferentially within a clinical trial. In the last years, preoperative neoadjuvant therapy was examined in order to obtain better local control and remove potential micrometastasis of the disease. A recent relative studies established that neoadjuvant therapy could recover resectability of the disease through down-staging of the tumor, particularly in borderline pancreatic cancers. Afterward neoadjuvant treatment, surgical examination is considered with preferable tumor response noticed by restaging imaging assessment. Then, resection or palliative operative procedures could be performed contingent on the intraoperative findings. Unresectable pancreatic cancers, both locally progressive and metastatic, might be detected with imaging for staging and resectability assessment or exposed during surgical exploration for patients initially considered as potentially resectable. After biopsy approval, the patient’s performance status is evaluated, where patients with good performance status might perhaps be able to tolerate more aggressive treatment. A considerable proportion of patients with pancreatic cancer require palliative interventions to relieve symptoms and safeguard optimal quality of life. Biliary obstruction is one of the most common simple circumstances in patients with pancreatic cancer. Placement of self-expanding metal stents is the favoured method to relieve biliary obstacle in patients with unresectable disease, as it is related with lower rates of, and longer time to, recurring biliary obstruction as compared to plastic stents, resulting in less cholangitis. Most patients with locally progressive or metastatic pancreatic cancer grow cancerrelated pain. The mainstay of pain management in these patients is administration of painkillers. However, for those whose analgesic control demonstrations inadequate or with unwanted side effects, EUS- or image-guided celiac plexus neurolysis could meaningfully improve pain relief. Furthermore, the risk of emerging venous thromboembolism is substantially increased in patients with pancreatic cancer. Low molecular weight heparin is rather administered, as randomized clinical trials indicated significantly reduced incidence of venous thromboembolism associated with intake of low molecular weight heparins.

Conclusion

Even with the newest efforts for novel therapeutic strategies, especially new chemo (radio) therapy regimens in (neo) adjuvant settings and better surgical options, the clinical outcome of patients with pancreatic cancer leftovers disappointing. Clinically, anticipate a higher amount of neoadjuvant therapeutic approaches for patients with non-metastatic pancreatic cancer in the nearby future; though, a better sympathetic of the underlying molecular mechanisms of this disease is of central position to design new therapeutic strategies for all patients. For molecular testing of pancreatic cancer, an adapted therapeutic concept for each patient might be obtainable, thus leading to a better prediction of the patient’s prognosis, a better prediction of the efficiency of the obtainable chemotherapeutics, and finally development in the patient’s outcome.